trending Market Intelligence /marketintelligence/en/news-insights/trending/G7hItiP4WXXSTgU6CGkP6A2 content esgSubNav
In This List

Axsome Therapeutics closes $9.5M direct offering of common stock, warrants

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Axsome Therapeutics closes $9.5M direct offering of common stock, warrants

Axsome Therapeutics Inc. closed its registered direct offering to certain institutional investors, raising gross proceeds of about $9.5 million.

The company sold 1,783,587 common shares and warrants to purchase up to an additional 1,783,587 shares priced at $5.325 per share and related warrants under the offering.

The warrants, which have a term of 53 weeks, are exercisable at $5.25 per share and are immediately exercisable upon issuance.

Axsome plans to use the net proceeds for the clinical development of AXS-07, other clinical programs and working capital and general corporate purposes.

H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.